Medicenna Therapeutics Corp (TSE:MDNA) has released an update.
Medicenna Therapeutics Corp. will showcase new clinical and preclinical immunotherapy data at the upcoming SITC conference, including updates on their MDNA11 study for treating advanced solid tumors and novel findings on MDNA113 and IL-2 agonists for glioblastoma. The data promise to enhance understanding of their therapies’ efficacy and tumor-targeting capabilities.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.
